Globus Medical, Inc. $GMED Shares Sold by BLI Banque de Luxembourg Investments

BLI Banque de Luxembourg Investments trimmed its position in shares of Globus Medical, Inc. (NYSE:GMED) by 31.9% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 136,500 shares of the medical device company’s stock after selling 63,900 shares during the quarter. BLI Banque de Luxembourg Investments’ holdings in Globus Medical were worth $12,002,000 at the end of the most recent quarter.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. SBI Securities Co. Ltd. boosted its holdings in Globus Medical by 98.2% during the 4th quarter. SBI Securities Co. Ltd. now owns 337 shares of the medical device company’s stock valued at $29,000 after acquiring an additional 167 shares during the period. Advisory Services Network LLC purchased a new position in shares of Globus Medical in the 3rd quarter valued at about $26,000. EverSource Wealth Advisors LLC boosted its stake in shares of Globus Medical by 74.3% in the 2nd quarter. EverSource Wealth Advisors LLC now owns 462 shares of the medical device company’s stock valued at $27,000 after buying an additional 197 shares during the period. Larson Financial Group LLC boosted its stake in shares of Globus Medical by 83.4% in the 4th quarter. Larson Financial Group LLC now owns 532 shares of the medical device company’s stock valued at $46,000 after buying an additional 242 shares during the period. Finally, Parallel Advisors LLC boosted its stake in shares of Globus Medical by 45.1% in the 3rd quarter. Parallel Advisors LLC now owns 557 shares of the medical device company’s stock valued at $32,000 after buying an additional 173 shares during the period. 95.16% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently issued reports on GMED. Barclays lifted their price objective on Globus Medical from $118.00 to $123.00 and gave the company an “overweight” rating in a research note on Wednesday, February 25th. Royal Bank Of Canada lifted their price objective on Globus Medical from $115.00 to $120.00 and gave the company an “outperform” rating in a research note on Friday, May 8th. Weiss Ratings reiterated a “hold (c+)” rating on shares of Globus Medical in a research note on Wednesday, April 15th. Truist Financial set a $115.00 price objective on Globus Medical in a research note on Wednesday, February 25th. Finally, Zacks Research upgraded Globus Medical from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, March 3rd. Two equities research analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and four have given a Hold rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $106.36.

Globus Medical Stock Down 2.1%

GMED stock opened at $78.36 on Tuesday. The business has a 50 day moving average price of $86.11 and a 200 day moving average price of $88.21. The stock has a market cap of $10.64 billion, a price-to-earnings ratio of 18.22, a PEG ratio of 1.65 and a beta of 0.95. Globus Medical, Inc. has a fifty-two week low of $51.79 and a fifty-two week high of $101.40.

Globus Medical (NYSE:GMED) last posted its earnings results on Thursday, May 7th. The medical device company reported $1.12 earnings per share for the quarter, topping the consensus estimate of $0.92 by $0.20. The firm had revenue of $759.85 million during the quarter, compared to analysts’ expectations of $740.35 million. Globus Medical had a return on equity of 13.46% and a net margin of 18.92%.The firm’s revenue was up 27.0% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.68 earnings per share. Globus Medical has set its FY 2026 guidance at 4.700-4.800 EPS. As a group, sell-side analysts anticipate that Globus Medical, Inc. will post 4.74 EPS for the current year.

Globus Medical Company Profile

Globus Medical, Inc (NYSE:GMED) is a leading medical device company specializing in musculoskeletal solutions for spine and orthopaedic applications. Founded in 2003 by David C. Paul and headquartered in Audubon, Pennsylvania, the company develops, manufactures and markets implantable devices and surgical instruments designed to treat spinal disorders and promote bone healing. Its product portfolio encompasses solutions for minimally invasive and open surgical procedures, including interbody fusion devices, pedicle screw systems, and biologics used to enhance fusion outcomes.

In addition to its core spine business, Globus Medical has expanded into robotics and navigation systems to support precision and efficiency in the operating room.